Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30720711 | 0.98 | CHRM2 (0.41) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3646616 | 0.98 | CHRM2 (0.41) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL3645858 | 0.89 | CHRM2 (0.46) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL31370737 | 0.89 | CHRM2 (0.46) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| Biphenyl SCHEMBL27742551 | 0.88 | HPGDS (0.51) | MEN1KMT2AHPGDSSLC18A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3795018 | 0.87 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HTR2C | |
| SCHEMBL498175 | 0.85 | — | — | |
| Tert-Butyl Formate SCHEMBL27746001 | 0.81 | TDP1 (0.34) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL577126 | 0.81 | — | — | |
| SCHEMBL497630 | 0.81 | TSHR (0.38) | MEN1KMT2ADRD4NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119707930-A | Aromatic ring compound and its prepn and use | 甘李药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024026486-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026484-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-101027560-A | Human G protein-coupled receptor for the treatment of hyperglycemia and related disorders and its modulator | ARENA PHARM INC (US) | 2007-08-29 | — | — | CN | disclosed |
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-22 | — | — | US | disclosed |
| EP-1735622-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005116653-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-0673432-B1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1999-03-24 | — | — | EP | disclosed |
| US-5869299-A | USING AN ENZYME SYSTEM FROM STREPTOMYCES, PARTICULARLY S. CLAVULIGERUS. | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-02-09 | — | — | US | disclosed |
| EP-0858457-A1 | 5-MEMBERED HETEROCYCLES, PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AND METHODS OF PRODUCING THEM | Dr. Karl Thomae GmbH (DE) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997015567-A1 | 5-MEMBERED HETEROCYCLES, PHARMACEUTICAL AGENTS CONTAINING SAID COMPOUNDS AND THE USE THEREOF AND METHODS OF PRODUCING THEM | DR. KARL THOMAE GMBH (DE) | 1997-05-01 | — | — | WO | disclosed |
| EP-0673432-A1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994012654-A1 | PROCESS FOR PREPARING CLAVULANIC ACID | SMITHKLINE BEECHAM PLC (GB) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043083-A1 | Thiazolyl piperidine derivatives | HRH3, HRH4, H1-3 | CHRM2 39/4885CHRM1 35/4885CHRM3 59/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | CHRM2 4411/4885CHRM1 4160/4885CHRM3 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.